USP Medicine Supply Map Reviews Global API Manufacturing
New report released by USP offers a look into API supply-chain vulnerabilities.
US Pharmacopeia (USP), an independent scientific organization, announced on March 16, 2022 that its USP Medicine Supply Vulnerability Insights Series reveals vulnerabilities in global API supply.
The first conclusion released from the Series discusses the significance of large Indian facilities in the manufacturing of API. There are currently 114 facilities in India with more than 30 active US-approved API products, which is significantly higher than any other region of the world.
The 40 external datasets and 250 million data points provided by the Medicine Supply Map show a comprehensive view of the upstream pharmaceutical supply chain. This information can aid in directing regulatory actions to protect against over-concentrated sources of API and build supply resilience.
“USP’s Medicine Supply Map is an innovative early warning system to help identify ingredient and finished product at risk of shortage so providers, manufacturers and governments can take actions to help prevent the shortage from occurring,” commented Ronald T. Piervincenzi, USP CEO. “Without visibility into the medicine supply chain, preparing for the next crisis is not possible.”
“The USP Medicine Supply Map is helping us identify upstream vulnerabilities in the supply chain for various essential medicines and determine those where Phlow’s capabilities in advanced manufacturing can have the biggest impact,” added Dave Levin, MD, chief medical and information officer of Phlow Corp., a US-based pharmaceutical company.
Source: USP
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
